Commentary
Video
AUA 2024: Dr. Cookson discusses prostate cancer research
Author(s):
Michael S. Cookson, MD, MMHC, FACS, recaps several presentations on prostate cancer from the 2024 American Urological Association Annual Meeting in San Antonio, Texas.
In this video, Michael S. Cookson, MD, MMHC, FACS, recaps several presentations from the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Cookson, a professor and the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City, is a co–editor in chief for Urology Times.
The following research is discussed:
1. MP60-18 (Lowentritt et al): Darolutamide real-world doublet and triplet utilization in metastatic hormone sensitive prostate cancer (mHSPC): US community urology setting
2. P2-07 (Shore et al): Apalutamide for high-risk localized prostate cancer following radical prostatectomy in Apa-RP: a multicenter, open-label, single-arm phase 2 study
3. PD01-03 (Gotto et al): Third interim analysis (IA3) of the DARolutamide Observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
4. P2-04 (Shore et al): Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)
